NovImmune successfully completes NI-0801 Phase I clinical study
Chemokines are a group of low molecular weight proteins that induce the chemotaxis of different leukocytes to sites of injury or infection. IP-10 is constitutively expressed at low levels in thymic, splenic and lymph node stroma tissues, but its expression can be induced on a variety of cell types including endothelial cells, keratinocytes, fibroblasts, monocytes and neutrophils. IP-10 not only mediates leukocyte recruitment, but also drives T-cell proliferation upon antigenic stimulation. Cell migration in response to chemoattractants requires the retention of IP-10, which is also true for all other chemokines, in the vicinity of the site of inflammation to make sure cells are recruited where they are needed.
IP-10 expression at sites of inflammation, leads to local accumulation of specialized cells responsible for the inflammation process in a number of different autoimmune conditions including psoriasis, multiple sclerosis, ulcerative colitis, rheumatoid arthritis, atherosclerosis, liver fibrosis and sarcoidosis. Dr Penelope Ward, Chief Medical Officer commented that ‘since increased IP-10 (CXCL10) levels correlate with disease severity, an ability to neutralize its effects with a target specific monoclonal antibody offers a promising strategy for the treatment of diseases such as liver fibrosis and lupus, for which therapeutic options are currently limited.'
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.